Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

NEXT STORY
Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
PREV STORY
G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Amid the COVID-19 crisis and the looming economic recession, the Peptic Ulcer Testing market worldwide will grow by a projected US$153.3 Million, during the analysis period

author_avatar
NASDAQ Market News

Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech

PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech ...

author_avatar
NASDAQ Market News

BioXcel Therapeutics Announces Primary and Secondary Endpoints Met in Two Pivotal Phase 3 Trials of BXCL501 for the Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

author_avatar
NASDAQ Market News